Last reviewed · How we verify
Asceniv™
Asceniv is an intravenous immunoglobulin (IVIG) replacement therapy that provides polyclonal antibodies to boost immune function in patients with primary immunodeficiency.
Asceniv is an intravenous immunoglobulin (IVIG) replacement therapy that provides polyclonal antibodies to boost immune function in patients with primary immunodeficiency. Used for Primary immunodeficiency (PI) disorders.
At a glance
| Generic name | Asceniv™ |
|---|---|
| Sponsor | ADMA Biologics, Inc. |
| Drug class | Intravenous immunoglobulin (IVIG) |
| Target | Polyclonal immunoglobulins (IgG) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Asceniv is a human immune globulin intravenous (human) product derived from pooled human plasma. It contains a broad spectrum of antibodies that help replace deficient or dysfunctional immunoglobulins in patients with primary immunodeficiency disorders, thereby restoring immune competence and reducing infection risk.
Approved indications
- Primary immunodeficiency (PI) disorders
Common side effects
- Headache
- Fever
- Chills
- Fatigue
- Infusion site reactions
- Thromboembolism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Asceniv™ CI brief — competitive landscape report
- Asceniv™ updates RSS · CI watch RSS
- ADMA Biologics, Inc. portfolio CI